nodes	percent_of_prediction	percent_of_DWPC	metapath
Dapagliflozin—CYP1A1—Cholecalciferol—osteoporosis	0.0662	0.111	CbGbCtD
Dapagliflozin—CYP1A2—Estropipate—osteoporosis	0.0574	0.0965	CbGbCtD
Dapagliflozin—CYP1A1—Estradiol—osteoporosis	0.0533	0.0897	CbGbCtD
Dapagliflozin—CYP2C9—Estropipate—osteoporosis	0.0517	0.0869	CbGbCtD
Dapagliflozin—ABCB1—Ethinyl Estradiol—osteoporosis	0.0323	0.0544	CbGbCtD
Dapagliflozin—CYP3A4—Estropipate—osteoporosis	0.0301	0.0506	CbGbCtD
Dapagliflozin—CYP3A4—Calcitriol—osteoporosis	0.0301	0.0506	CbGbCtD
Dapagliflozin—CYP1A2—Conjugated Estrogens—osteoporosis	0.0271	0.0456	CbGbCtD
Dapagliflozin—CYP2C9—Cholecalciferol—osteoporosis	0.0266	0.0448	CbGbCtD
Dapagliflozin—CYP2D6—Cholecalciferol—osteoporosis	0.0243	0.041	CbGbCtD
Dapagliflozin—CYP3A4—Ergocalciferol—osteoporosis	0.024	0.0404	CbGbCtD
Dapagliflozin—CYP1A2—Estradiol—osteoporosis	0.0238	0.0401	CbGbCtD
Dapagliflozin—ABCB1—Conjugated Estrogens—osteoporosis	0.0237	0.0399	CbGbCtD
Dapagliflozin—CYP2C9—Estradiol—osteoporosis	0.0215	0.0361	CbGbCtD
Dapagliflozin—ABCB1—Estradiol—osteoporosis	0.0208	0.035	CbGbCtD
Dapagliflozin—CYP3A4—Raloxifene—osteoporosis	0.0201	0.0337	CbGbCtD
Dapagliflozin—CYP3A4—Ethinyl Estradiol—osteoporosis	0.0194	0.0326	CbGbCtD
Dapagliflozin—CYP3A4—Cholecalciferol—osteoporosis	0.0155	0.026	CbGbCtD
Dapagliflozin—CYP3A4—Conjugated Estrogens—osteoporosis	0.0142	0.0239	CbGbCtD
Dapagliflozin—CYP3A4—Estradiol—osteoporosis	0.0125	0.021	CbGbCtD
Dapagliflozin—Myocardial infarction—Ethinyl Estradiol—osteoporosis	0.00062	0.00209	CcSEcCtD
Dapagliflozin—Infestation NOS—Risedronate—osteoporosis	0.000617	0.00207	CcSEcCtD
Dapagliflozin—Infestation—Risedronate—osteoporosis	0.000617	0.00207	CcSEcCtD
Dapagliflozin—Urinary tract infection—Ethinyl Estradiol—osteoporosis	0.000615	0.00207	CcSEcCtD
Dapagliflozin—Polyuria—Estradiol—osteoporosis	0.00061	0.00205	CcSEcCtD
Dapagliflozin—Malnutrition—Estropipate—osteoporosis	0.00061	0.00205	CcSEcCtD
Dapagliflozin—Influenza—Zoledronate—osteoporosis	0.0006	0.00202	CcSEcCtD
Dapagliflozin—Urinary tract infection—Risedronate—osteoporosis	0.000599	0.00202	CcSEcCtD
Dapagliflozin—Discomfort—Etidronic acid—osteoporosis	0.000593	0.00199	CcSEcCtD
Dapagliflozin—Back pain—Estropipate—osteoporosis	0.00059	0.00198	CcSEcCtD
Dapagliflozin—Infestation—Pamidronate—osteoporosis	0.000586	0.00197	CcSEcCtD
Dapagliflozin—Infestation NOS—Pamidronate—osteoporosis	0.000586	0.00197	CcSEcCtD
Dapagliflozin—Malnutrition—Ibandronate—osteoporosis	0.000585	0.00197	CcSEcCtD
Dapagliflozin—Dizziness—Calcium Acetate—osteoporosis	0.000579	0.00195	CcSEcCtD
Dapagliflozin—Influenza—Conjugated Estrogens—osteoporosis	0.000578	0.00195	CcSEcCtD
Dapagliflozin—Renal failure—Pamidronate—osteoporosis	0.000576	0.00194	CcSEcCtD
Dapagliflozin—Infection—Etidronic acid—osteoporosis	0.000571	0.00192	CcSEcCtD
Dapagliflozin—Urinary tract infection—Pamidronate—osteoporosis	0.00057	0.00192	CcSEcCtD
Dapagliflozin—Back pain—Ibandronate—osteoporosis	0.000566	0.0019	CcSEcCtD
Dapagliflozin—Urinary tract disorder—Ethinyl Estradiol—osteoporosis	0.000561	0.00189	CcSEcCtD
Dapagliflozin—Connective tissue disorder—Ethinyl Estradiol—osteoporosis	0.000558	0.00188	CcSEcCtD
Dapagliflozin—Angioedema—Estropipate—osteoporosis	0.000557	0.00187	CcSEcCtD
Dapagliflozin—Urethral disorder—Ethinyl Estradiol—osteoporosis	0.000556	0.00187	CcSEcCtD
Dapagliflozin—Pollakiuria—Zoledronate—osteoporosis	0.000555	0.00187	CcSEcCtD
Dapagliflozin—Angioedema—Alendronate—osteoporosis	0.000549	0.00185	CcSEcCtD
Dapagliflozin—Urinary tract disorder—Risedronate—osteoporosis	0.000547	0.00184	CcSEcCtD
Dapagliflozin—Cerebrovascular accident—Estradiol—osteoporosis	0.000546	0.00184	CcSEcCtD
Dapagliflozin—Connective tissue disorder—Risedronate—osteoporosis	0.000544	0.00183	CcSEcCtD
Dapagliflozin—Urethral disorder—Risedronate—osteoporosis	0.000543	0.00183	CcSEcCtD
Dapagliflozin—Dysuria—Conjugated Estrogens—osteoporosis	0.000541	0.00182	CcSEcCtD
Dapagliflozin—Pain in extremity—Estradiol—osteoporosis	0.000535	0.0018	CcSEcCtD
Dapagliflozin—Infestation NOS—Zoledronate—osteoporosis	0.000535	0.0018	CcSEcCtD
Dapagliflozin—Infestation—Zoledronate—osteoporosis	0.000535	0.0018	CcSEcCtD
Dapagliflozin—Angioedema—Ibandronate—osteoporosis	0.000534	0.0018	CcSEcCtD
Dapagliflozin—Renal failure—Zoledronate—osteoporosis	0.000526	0.00177	CcSEcCtD
Dapagliflozin—Urinary tract infection—Zoledronate—osteoporosis	0.00052	0.00175	CcSEcCtD
Dapagliflozin—Nausea—Calcium Acetate—osteoporosis	0.00052	0.00175	CcSEcCtD
Dapagliflozin—Urinary tract disorder—Pamidronate—osteoporosis	0.00052	0.00175	CcSEcCtD
Dapagliflozin—Connective tissue disorder—Pamidronate—osteoporosis	0.000517	0.00174	CcSEcCtD
Dapagliflozin—Urethral disorder—Pamidronate—osteoporosis	0.000516	0.00174	CcSEcCtD
Dapagliflozin—Infestation NOS—Conjugated Estrogens—osteoporosis	0.000515	0.00173	CcSEcCtD
Dapagliflozin—Infestation—Conjugated Estrogens—osteoporosis	0.000515	0.00173	CcSEcCtD
Dapagliflozin—Unspecified disorder of skin and subcutaneous tissue—Estropipate—osteoporosis	0.000515	0.00173	CcSEcCtD
Dapagliflozin—Acute coronary syndrome—Conjugated Estrogens—osteoporosis	0.000508	0.00171	CcSEcCtD
Dapagliflozin—Renal failure—Conjugated Estrogens—osteoporosis	0.000507	0.0017	CcSEcCtD
Dapagliflozin—Myocardial infarction—Conjugated Estrogens—osteoporosis	0.000505	0.0017	CcSEcCtD
Dapagliflozin—Discomfort—Alendronate—osteoporosis	0.000505	0.0017	CcSEcCtD
Dapagliflozin—Hypertension—Ibandronate—osteoporosis	0.000505	0.0017	CcSEcCtD
Dapagliflozin—Unspecified disorder of skin and subcutaneous tissue—Raloxifene—osteoporosis	0.000499	0.00168	CcSEcCtD
Dapagliflozin—Anaphylactic shock—Estropipate—osteoporosis	0.000498	0.00167	CcSEcCtD
Dapagliflozin—Oedema—Estropipate—osteoporosis	0.000498	0.00167	CcSEcCtD
Dapagliflozin—Infection—Estropipate—osteoporosis	0.000494	0.00166	CcSEcCtD
Dapagliflozin—Unspecified disorder of skin and subcutaneous tissue—Ibandronate—osteoporosis	0.000494	0.00166	CcSEcCtD
Dapagliflozin—Malnutrition—Ethinyl Estradiol—osteoporosis	0.000494	0.00166	CcSEcCtD
Dapagliflozin—Hypertension—Calcitriol—osteoporosis	0.000494	0.00166	CcSEcCtD
Dapagliflozin—Constipation—Etidronic acid—osteoporosis	0.000492	0.00165	CcSEcCtD
Dapagliflozin—Discomfort—Ibandronate—osteoporosis	0.000492	0.00165	CcSEcCtD
Dapagliflozin—Infection—Alendronate—osteoporosis	0.000487	0.00164	CcSEcCtD
Dapagliflozin—Skin disorder—Estropipate—osteoporosis	0.000483	0.00163	CcSEcCtD
Dapagliflozin—Malnutrition—Risedronate—osteoporosis	0.000482	0.00162	CcSEcCtD
Dapagliflozin—Discomfort—Calcitriol—osteoporosis	0.000481	0.00162	CcSEcCtD
Dapagliflozin—Infection—Raloxifene—osteoporosis	0.000479	0.00161	CcSEcCtD
Dapagliflozin—Nasopharyngitis—Estradiol—osteoporosis	0.000479	0.00161	CcSEcCtD
Dapagliflozin—Back pain—Ethinyl Estradiol—osteoporosis	0.000478	0.00161	CcSEcCtD
Dapagliflozin—Anaphylactic shock—Ibandronate—osteoporosis	0.000477	0.00161	CcSEcCtD
Dapagliflozin—Urinary tract disorder—Zoledronate—osteoporosis	0.000475	0.0016	CcSEcCtD
Dapagliflozin—Infection—Ibandronate—osteoporosis	0.000474	0.00159	CcSEcCtD
Dapagliflozin—Connective tissue disorder—Zoledronate—osteoporosis	0.000472	0.00159	CcSEcCtD
Dapagliflozin—Urethral disorder—Zoledronate—osteoporosis	0.000471	0.00159	CcSEcCtD
Dapagliflozin—Skin disorder—Raloxifene—osteoporosis	0.000468	0.00158	CcSEcCtD
Dapagliflozin—Anaphylactic shock—Calcitriol—osteoporosis	0.000467	0.00157	CcSEcCtD
Dapagliflozin—Back pain—Risedronate—osteoporosis	0.000466	0.00157	CcSEcCtD
Dapagliflozin—Hyperhidrosis—Raloxifene—osteoporosis	0.000466	0.00157	CcSEcCtD
Dapagliflozin—Skin disorder—Ibandronate—osteoporosis	0.000463	0.00156	CcSEcCtD
Dapagliflozin—Influenza—Estradiol—osteoporosis	0.000463	0.00156	CcSEcCtD
Dapagliflozin—Hyperhidrosis—Ibandronate—osteoporosis	0.000461	0.00155	CcSEcCtD
Dapagliflozin—Nausea—Ergocalciferol—osteoporosis	0.00046	0.00155	CcSEcCtD
Dapagliflozin—Malnutrition—Pamidronate—osteoporosis	0.000458	0.00154	CcSEcCtD
Dapagliflozin—Urticaria—Etidronic acid—osteoporosis	0.000457	0.00154	CcSEcCtD
Dapagliflozin—Skin disorder—Calcitriol—osteoporosis	0.000454	0.00153	CcSEcCtD
Dapagliflozin—Angioedema—Ethinyl Estradiol—osteoporosis	0.000452	0.00152	CcSEcCtD
Dapagliflozin—Back pain—Pamidronate—osteoporosis	0.000443	0.00149	CcSEcCtD
Dapagliflozin—Angioedema—Risedronate—osteoporosis	0.00044	0.00148	CcSEcCtD
Dapagliflozin—Gastrointestinal disorder—Estropipate—osteoporosis	0.00043	0.00145	CcSEcCtD
Dapagliflozin—Pollakiuria—Estradiol—osteoporosis	0.000427	0.00144	CcSEcCtD
Dapagliflozin—Constipation—Estropipate—osteoporosis	0.000425	0.00143	CcSEcCtD
Dapagliflozin—Hypersensitivity—Etidronic acid—osteoporosis	0.000424	0.00143	CcSEcCtD
Dapagliflozin—Constipation—Alendronate—osteoporosis	0.000419	0.00141	CcSEcCtD
Dapagliflozin—Angioedema—Pamidronate—osteoporosis	0.000419	0.00141	CcSEcCtD
Dapagliflozin—Malnutrition—Zoledronate—osteoporosis	0.000418	0.00141	CcSEcCtD
Dapagliflozin—Unspecified disorder of skin and subcutaneous tissue—Ethinyl Estradiol—osteoporosis	0.000418	0.00141	CcSEcCtD
Dapagliflozin—Gastrointestinal disorder—Raloxifene—osteoporosis	0.000416	0.0014	CcSEcCtD
Dapagliflozin—Hypertension—Risedronate—osteoporosis	0.000416	0.0014	CcSEcCtD
Dapagliflozin—Discomfort—Ethinyl Estradiol—osteoporosis	0.000416	0.0014	CcSEcCtD
Dapagliflozin—Infestation NOS—Estradiol—osteoporosis	0.000413	0.00139	CcSEcCtD
Dapagliflozin—Infestation—Estradiol—osteoporosis	0.000413	0.00139	CcSEcCtD
Dapagliflozin—Gastrointestinal disorder—Ibandronate—osteoporosis	0.000412	0.00139	CcSEcCtD
Dapagliflozin—Constipation—Ibandronate—osteoporosis	0.000408	0.00137	CcSEcCtD
Dapagliflozin—Unspecified disorder of skin and subcutaneous tissue—Risedronate—osteoporosis	0.000407	0.00137	CcSEcCtD
Dapagliflozin—Acute coronary syndrome—Estradiol—osteoporosis	0.000407	0.00137	CcSEcCtD
Dapagliflozin—Back pain—Zoledronate—osteoporosis	0.000405	0.00136	CcSEcCtD
Dapagliflozin—Myocardial infarction—Estradiol—osteoporosis	0.000404	0.00136	CcSEcCtD
Dapagliflozin—Oedema—Ethinyl Estradiol—osteoporosis	0.000403	0.00136	CcSEcCtD
Dapagliflozin—Malnutrition—Conjugated Estrogens—osteoporosis	0.000403	0.00136	CcSEcCtD
Dapagliflozin—Urinary tract infection—Estradiol—osteoporosis	0.000401	0.00135	CcSEcCtD
Dapagliflozin—Infection—Ethinyl Estradiol—osteoporosis	0.000401	0.00135	CcSEcCtD
Dapagliflozin—Constipation—Calcitriol—osteoporosis	0.000399	0.00134	CcSEcCtD
Dapagliflozin—Hypertension—Pamidronate—osteoporosis	0.000395	0.00133	CcSEcCtD
Dapagliflozin—Urticaria—Estropipate—osteoporosis	0.000395	0.00133	CcSEcCtD
Dapagliflozin—Body temperature increased—Estropipate—osteoporosis	0.000393	0.00132	CcSEcCtD
Dapagliflozin—Skin disorder—Ethinyl Estradiol—osteoporosis	0.000392	0.00132	CcSEcCtD
Dapagliflozin—Infection—Risedronate—osteoporosis	0.000391	0.00131	CcSEcCtD
Dapagliflozin—Back pain—Conjugated Estrogens—osteoporosis	0.00039	0.00131	CcSEcCtD
Dapagliflozin—Urticaria—Alendronate—osteoporosis	0.000389	0.00131	CcSEcCtD
Dapagliflozin—Body temperature increased—Alendronate—osteoporosis	0.000387	0.0013	CcSEcCtD
Dapagliflozin—Discomfort—Pamidronate—osteoporosis	0.000385	0.0013	CcSEcCtD
Dapagliflozin—Angioedema—Zoledronate—osteoporosis	0.000382	0.00129	CcSEcCtD
Dapagliflozin—Skin disorder—Risedronate—osteoporosis	0.000382	0.00129	CcSEcCtD
Dapagliflozin—Body temperature increased—Raloxifene—osteoporosis	0.000381	0.00128	CcSEcCtD
Dapagliflozin—Urticaria—Ibandronate—osteoporosis	0.000379	0.00128	CcSEcCtD
Dapagliflozin—Body temperature increased—Ibandronate—osteoporosis	0.000377	0.00127	CcSEcCtD
Dapagliflozin—Oedema—Pamidronate—osteoporosis	0.000374	0.00126	CcSEcCtD
Dapagliflozin—Anaphylactic shock—Pamidronate—osteoporosis	0.000374	0.00126	CcSEcCtD
Dapagliflozin—Infection—Pamidronate—osteoporosis	0.000371	0.00125	CcSEcCtD
Dapagliflozin—Urticaria—Calcitriol—osteoporosis	0.000371	0.00125	CcSEcCtD
Dapagliflozin—Body temperature increased—Calcitriol—osteoporosis	0.000369	0.00124	CcSEcCtD
Dapagliflozin—Angioedema—Conjugated Estrogens—osteoporosis	0.000368	0.00124	CcSEcCtD
Dapagliflozin—Hypersensitivity—Estropipate—osteoporosis	0.000367	0.00123	CcSEcCtD
Dapagliflozin—Urinary tract disorder—Estradiol—osteoporosis	0.000366	0.00123	CcSEcCtD
Dapagliflozin—Connective tissue disorder—Estradiol—osteoporosis	0.000364	0.00122	CcSEcCtD
Dapagliflozin—Urethral disorder—Estradiol—osteoporosis	0.000363	0.00122	CcSEcCtD
Dapagliflozin—Rash—Etidronic acid—osteoporosis	0.000363	0.00122	CcSEcCtD
Dapagliflozin—Dermatitis—Etidronic acid—osteoporosis	0.000362	0.00122	CcSEcCtD
Dapagliflozin—Hyperhidrosis—Pamidronate—osteoporosis	0.000361	0.00122	CcSEcCtD
Dapagliflozin—Hypertension—Zoledronate—osteoporosis	0.000361	0.00122	CcSEcCtD
Dapagliflozin—Hypersensitivity—Alendronate—osteoporosis	0.000361	0.00121	CcSEcCtD
Dapagliflozin—Headache—Etidronic acid—osteoporosis	0.00036	0.00121	CcSEcCtD
Dapagliflozin—Unspecified disorder of skin and subcutaneous tissue—Zoledronate—osteoporosis	0.000354	0.00119	CcSEcCtD
Dapagliflozin—Discomfort—Zoledronate—osteoporosis	0.000352	0.00118	CcSEcCtD
Dapagliflozin—Hypersensitivity—Ibandronate—osteoporosis	0.000352	0.00118	CcSEcCtD
Dapagliflozin—Hypotension—Pamidronate—osteoporosis	0.000349	0.00118	CcSEcCtD
Dapagliflozin—Gastrointestinal disorder—Ethinyl Estradiol—osteoporosis	0.000348	0.00117	CcSEcCtD
Dapagliflozin—Constipation—Ethinyl Estradiol—osteoporosis	0.000345	0.00116	CcSEcCtD
Dapagliflozin—Hypersensitivity—Calcitriol—osteoporosis	0.000344	0.00116	CcSEcCtD
Dapagliflozin—Nausea—Etidronic acid—osteoporosis	0.000342	0.00115	CcSEcCtD
Dapagliflozin—Anaphylactic shock—Zoledronate—osteoporosis	0.000341	0.00115	CcSEcCtD
Dapagliflozin—Oedema—Zoledronate—osteoporosis	0.000341	0.00115	CcSEcCtD
Dapagliflozin—Unspecified disorder of skin and subcutaneous tissue—Conjugated Estrogens—osteoporosis	0.000341	0.00115	CcSEcCtD
Dapagliflozin—Gastrointestinal disorder—Risedronate—osteoporosis	0.000339	0.00114	CcSEcCtD
Dapagliflozin—Infection—Zoledronate—osteoporosis	0.000339	0.00114	CcSEcCtD
Dapagliflozin—Constipation—Risedronate—osteoporosis	0.000336	0.00113	CcSEcCtD
Dapagliflozin—Skin disorder—Zoledronate—osteoporosis	0.000332	0.00112	CcSEcCtD
Dapagliflozin—Hyperhidrosis—Zoledronate—osteoporosis	0.00033	0.00111	CcSEcCtD
Dapagliflozin—Dizziness—Estropipate—osteoporosis	0.000329	0.00111	CcSEcCtD
Dapagliflozin—Oedema—Conjugated Estrogens—osteoporosis	0.000329	0.00111	CcSEcCtD
Dapagliflozin—Anaphylactic shock—Conjugated Estrogens—osteoporosis	0.000329	0.00111	CcSEcCtD
Dapagliflozin—Infection—Conjugated Estrogens—osteoporosis	0.000327	0.0011	CcSEcCtD
Dapagliflozin—Dizziness—Alendronate—osteoporosis	0.000324	0.00109	CcSEcCtD
Dapagliflozin—Gastrointestinal disorder—Pamidronate—osteoporosis	0.000323	0.00109	CcSEcCtD
Dapagliflozin—Malnutrition—Estradiol—osteoporosis	0.000322	0.00108	CcSEcCtD
Dapagliflozin—Urticaria—Ethinyl Estradiol—osteoporosis	0.00032	0.00108	CcSEcCtD
Dapagliflozin—Constipation—Pamidronate—osteoporosis	0.00032	0.00108	CcSEcCtD
Dapagliflozin—Skin disorder—Conjugated Estrogens—osteoporosis	0.000319	0.00107	CcSEcCtD
Dapagliflozin—Hypotension—Zoledronate—osteoporosis	0.000319	0.00107	CcSEcCtD
Dapagliflozin—Body temperature increased—Ethinyl Estradiol—osteoporosis	0.000319	0.00107	CcSEcCtD
Dapagliflozin—Dizziness—Raloxifene—osteoporosis	0.000319	0.00107	CcSEcCtD
Dapagliflozin—Hyperhidrosis—Conjugated Estrogens—osteoporosis	0.000318	0.00107	CcSEcCtD
Dapagliflozin—Dizziness—Ibandronate—osteoporosis	0.000316	0.00106	CcSEcCtD
Dapagliflozin—Rash—Estropipate—osteoporosis	0.000314	0.00106	CcSEcCtD
Dapagliflozin—Dermatitis—Estropipate—osteoporosis	0.000313	0.00105	CcSEcCtD
Dapagliflozin—Urticaria—Risedronate—osteoporosis	0.000312	0.00105	CcSEcCtD
Dapagliflozin—Back pain—Estradiol—osteoporosis	0.000312	0.00105	CcSEcCtD
Dapagliflozin—Headache—Estropipate—osteoporosis	0.000312	0.00105	CcSEcCtD
Dapagliflozin—Body temperature increased—Risedronate—osteoporosis	0.000311	0.00105	CcSEcCtD
Dapagliflozin—Rash—Alendronate—osteoporosis	0.000309	0.00104	CcSEcCtD
Dapagliflozin—Dermatitis—Alendronate—osteoporosis	0.000309	0.00104	CcSEcCtD
Dapagliflozin—Hypotension—Conjugated Estrogens—osteoporosis	0.000307	0.00103	CcSEcCtD
Dapagliflozin—Headache—Alendronate—osteoporosis	0.000307	0.00103	CcSEcCtD
Dapagliflozin—Rash—Raloxifene—osteoporosis	0.000304	0.00102	CcSEcCtD
Dapagliflozin—Dermatitis—Raloxifene—osteoporosis	0.000304	0.00102	CcSEcCtD
Dapagliflozin—Headache—Raloxifene—osteoporosis	0.000302	0.00102	CcSEcCtD
Dapagliflozin—Rash—Ibandronate—osteoporosis	0.000301	0.00101	CcSEcCtD
Dapagliflozin—Dermatitis—Ibandronate—osteoporosis	0.000301	0.00101	CcSEcCtD
Dapagliflozin—Headache—Ibandronate—osteoporosis	0.000299	0.00101	CcSEcCtD
Dapagliflozin—Hypersensitivity—Ethinyl Estradiol—osteoporosis	0.000297	0.001	CcSEcCtD
Dapagliflozin—Nausea—Estropipate—osteoporosis	0.000296	0.000994	CcSEcCtD
Dapagliflozin—Body temperature increased—Pamidronate—osteoporosis	0.000295	0.000994	CcSEcCtD
Dapagliflozin—Gastrointestinal disorder—Zoledronate—osteoporosis	0.000295	0.000992	CcSEcCtD
Dapagliflozin—Angioedema—Estradiol—osteoporosis	0.000295	0.000991	CcSEcCtD
Dapagliflozin—Rash—Calcitriol—osteoporosis	0.000294	0.000991	CcSEcCtD
Dapagliflozin—Dermatitis—Calcitriol—osteoporosis	0.000294	0.00099	CcSEcCtD
Dapagliflozin—Headache—Calcitriol—osteoporosis	0.000293	0.000984	CcSEcCtD
Dapagliflozin—Constipation—Zoledronate—osteoporosis	0.000292	0.000982	CcSEcCtD
Dapagliflozin—Nausea—Alendronate—osteoporosis	0.000291	0.000979	CcSEcCtD
Dapagliflozin—Hypersensitivity—Risedronate—osteoporosis	0.00029	0.000975	CcSEcCtD
Dapagliflozin—Nausea—Raloxifene—osteoporosis	0.000286	0.000963	CcSEcCtD
Dapagliflozin—Gastrointestinal disorder—Conjugated Estrogens—osteoporosis	0.000284	0.000955	CcSEcCtD
Dapagliflozin—Nausea—Ibandronate—osteoporosis	0.000283	0.000954	CcSEcCtD
Dapagliflozin—Constipation—Conjugated Estrogens—osteoporosis	0.000281	0.000946	CcSEcCtD
Dapagliflozin—Hypertension—Estradiol—osteoporosis	0.000278	0.000937	CcSEcCtD
Dapagliflozin—Nausea—Calcitriol—osteoporosis	0.000277	0.000933	CcSEcCtD
Dapagliflozin—Hypersensitivity—Pamidronate—osteoporosis	0.000275	0.000927	CcSEcCtD
Dapagliflozin—Unspecified disorder of skin and subcutaneous tissue—Estradiol—osteoporosis	0.000273	0.000917	CcSEcCtD
Dapagliflozin—Urticaria—Zoledronate—osteoporosis	0.000271	0.000913	CcSEcCtD
Dapagliflozin—Discomfort—Estradiol—osteoporosis	0.000271	0.000912	CcSEcCtD
Dapagliflozin—Body temperature increased—Zoledronate—osteoporosis	0.00027	0.000908	CcSEcCtD
Dapagliflozin—Dizziness—Ethinyl Estradiol—osteoporosis	0.000267	0.000897	CcSEcCtD
Dapagliflozin—Anaphylactic shock—Estradiol—osteoporosis	0.000263	0.000885	CcSEcCtD
Dapagliflozin—Oedema—Estradiol—osteoporosis	0.000263	0.000885	CcSEcCtD
Dapagliflozin—Infection—Estradiol—osteoporosis	0.000261	0.000879	CcSEcCtD
Dapagliflozin—Urticaria—Conjugated Estrogens—osteoporosis	0.000261	0.000879	CcSEcCtD
Dapagliflozin—Dizziness—Risedronate—osteoporosis	0.00026	0.000875	CcSEcCtD
Dapagliflozin—Body temperature increased—Conjugated Estrogens—osteoporosis	0.00026	0.000874	CcSEcCtD
Dapagliflozin—Skin disorder—Estradiol—osteoporosis	0.000256	0.00086	CcSEcCtD
Dapagliflozin—Hyperhidrosis—Estradiol—osteoporosis	0.000254	0.000856	CcSEcCtD
Dapagliflozin—Rash—Ethinyl Estradiol—osteoporosis	0.000254	0.000856	CcSEcCtD
Dapagliflozin—Dermatitis—Ethinyl Estradiol—osteoporosis	0.000254	0.000855	CcSEcCtD
Dapagliflozin—Headache—Ethinyl Estradiol—osteoporosis	0.000253	0.00085	CcSEcCtD
Dapagliflozin—Hypersensitivity—Zoledronate—osteoporosis	0.000252	0.000846	CcSEcCtD
Dapagliflozin—Rash—Risedronate—osteoporosis	0.000248	0.000834	CcSEcCtD
Dapagliflozin—Dermatitis—Risedronate—osteoporosis	0.000248	0.000833	CcSEcCtD
Dapagliflozin—Dizziness—Pamidronate—osteoporosis	0.000247	0.000832	CcSEcCtD
Dapagliflozin—Headache—Risedronate—osteoporosis	0.000246	0.000829	CcSEcCtD
Dapagliflozin—Hypersensitivity—Conjugated Estrogens—osteoporosis	0.000242	0.000815	CcSEcCtD
Dapagliflozin—Nausea—Ethinyl Estradiol—osteoporosis	0.00024	0.000806	CcSEcCtD
Dapagliflozin—Rash—Pamidronate—osteoporosis	0.000236	0.000793	CcSEcCtD
Dapagliflozin—Dermatitis—Pamidronate—osteoporosis	0.000235	0.000792	CcSEcCtD
Dapagliflozin—Headache—Pamidronate—osteoporosis	0.000234	0.000788	CcSEcCtD
Dapagliflozin—Nausea—Risedronate—osteoporosis	0.000234	0.000786	CcSEcCtD
Dapagliflozin—Gastrointestinal disorder—Estradiol—osteoporosis	0.000227	0.000764	CcSEcCtD
Dapagliflozin—Dizziness—Zoledronate—osteoporosis	0.000226	0.00076	CcSEcCtD
Dapagliflozin—Constipation—Estradiol—osteoporosis	0.000225	0.000757	CcSEcCtD
Dapagliflozin—Nausea—Pamidronate—osteoporosis	0.000222	0.000747	CcSEcCtD
Dapagliflozin—Dizziness—Conjugated Estrogens—osteoporosis	0.000217	0.000731	CcSEcCtD
Dapagliflozin—Rash—Zoledronate—osteoporosis	0.000215	0.000724	CcSEcCtD
Dapagliflozin—Dermatitis—Zoledronate—osteoporosis	0.000215	0.000724	CcSEcCtD
Dapagliflozin—Headache—Zoledronate—osteoporosis	0.000214	0.00072	CcSEcCtD
Dapagliflozin—Urticaria—Estradiol—osteoporosis	0.000209	0.000703	CcSEcCtD
Dapagliflozin—Body temperature increased—Estradiol—osteoporosis	0.000208	0.0007	CcSEcCtD
Dapagliflozin—Rash—Conjugated Estrogens—osteoporosis	0.000207	0.000697	CcSEcCtD
Dapagliflozin—Dermatitis—Conjugated Estrogens—osteoporosis	0.000207	0.000697	CcSEcCtD
Dapagliflozin—Headache—Conjugated Estrogens—osteoporosis	0.000206	0.000693	CcSEcCtD
Dapagliflozin—Nausea—Zoledronate—osteoporosis	0.000203	0.000682	CcSEcCtD
Dapagliflozin—Nausea—Conjugated Estrogens—osteoporosis	0.000195	0.000657	CcSEcCtD
Dapagliflozin—Hypersensitivity—Estradiol—osteoporosis	0.000194	0.000652	CcSEcCtD
Dapagliflozin—Dizziness—Estradiol—osteoporosis	0.000174	0.000585	CcSEcCtD
Dapagliflozin—Rash—Estradiol—osteoporosis	0.000166	0.000558	CcSEcCtD
Dapagliflozin—Dermatitis—Estradiol—osteoporosis	0.000166	0.000558	CcSEcCtD
Dapagliflozin—Headache—Estradiol—osteoporosis	0.000165	0.000555	CcSEcCtD
Dapagliflozin—Nausea—Estradiol—osteoporosis	0.000156	0.000526	CcSEcCtD
Dapagliflozin—UGT1A9—Metabolism of lipids and lipoproteins—CYP19A1—osteoporosis	6.24e-05	0.000576	CbGpPWpGaD
Dapagliflozin—ABCB1—Allograft Rejection—IL1B—osteoporosis	6.2e-05	0.000572	CbGpPWpGaD
Dapagliflozin—CYP2A6—Metabolism—ATIC—osteoporosis	6.16e-05	0.000569	CbGpPWpGaD
Dapagliflozin—CYP2A6—Metabolism—PNP—osteoporosis	6.16e-05	0.000569	CbGpPWpGaD
Dapagliflozin—UGT2B4—Metabolism—ADCY5—osteoporosis	6.14e-05	0.000567	CbGpPWpGaD
Dapagliflozin—UGT2B4—Metabolism—GPX1—osteoporosis	6.11e-05	0.000565	CbGpPWpGaD
Dapagliflozin—CYP1A2—Biological oxidations—CYP19A1—osteoporosis	5.95e-05	0.00055	CbGpPWpGaD
Dapagliflozin—CYP1A2—Aryl Hydrocarbon Receptor—MYC—osteoporosis	5.94e-05	0.000549	CbGpPWpGaD
Dapagliflozin—ABCB1—Transmembrane transport of small molecules—ANXA2—osteoporosis	5.93e-05	0.000548	CbGpPWpGaD
Dapagliflozin—CYP1A2—Aryl Hydrocarbon Receptor Pathway—TGFB1—osteoporosis	5.92e-05	0.000547	CbGpPWpGaD
Dapagliflozin—UGT2B7—Metabolism—TPI1—osteoporosis	5.89e-05	0.000544	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metapathway biotransformation—CYP19A1—osteoporosis	5.87e-05	0.000542	CbGpPWpGaD
Dapagliflozin—SLC5A1—Metabolism—POMC—osteoporosis	5.85e-05	0.00054	CbGpPWpGaD
Dapagliflozin—SLC5A2—Metabolism—POMC—osteoporosis	5.85e-05	0.00054	CbGpPWpGaD
Dapagliflozin—CYP1A1—Metabolism of lipids and lipoproteins—P4HB—osteoporosis	5.8e-05	0.000536	CbGpPWpGaD
Dapagliflozin—UGT2B4—Metabolism—MTHFR—osteoporosis	5.64e-05	0.000521	CbGpPWpGaD
Dapagliflozin—UGT1A9—Metabolism—IDH2—osteoporosis	5.63e-05	0.00052	CbGpPWpGaD
Dapagliflozin—CYP1A1—Biological oxidations—POMC—osteoporosis	5.61e-05	0.000518	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism of lipids and lipoproteins—OXCT1—osteoporosis	5.58e-05	0.000516	CbGpPWpGaD
Dapagliflozin—UGT2B7—Metabolism—P4HB—osteoporosis	5.54e-05	0.000511	CbGpPWpGaD
Dapagliflozin—CYP1A2—Aryl Hydrocarbon Receptor—TNF—osteoporosis	5.53e-05	0.000511	CbGpPWpGaD
Dapagliflozin—CYP1A2—Aryl Hydrocarbon Receptor Pathway—TNF—osteoporosis	5.53e-05	0.000511	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism of lipids and lipoproteins—MGLL—osteoporosis	5.44e-05	0.000503	CbGpPWpGaD
Dapagliflozin—UGT2B7—Metabolism—GAPDH—osteoporosis	5.43e-05	0.000502	CbGpPWpGaD
Dapagliflozin—SLC5A4—Disease—MYC—osteoporosis	5.32e-05	0.000492	CbGpPWpGaD
Dapagliflozin—SLC5A4—Disease—TGFB1—osteoporosis	5.31e-05	0.000491	CbGpPWpGaD
Dapagliflozin—UGT2B7—Metabolism—RAP1A—osteoporosis	5.29e-05	0.000489	CbGpPWpGaD
Dapagliflozin—CYP1A1—Metabolism—PKM—osteoporosis	5.29e-05	0.000489	CbGpPWpGaD
Dapagliflozin—CYP1A1—Metabolism—FDPS—osteoporosis	5.29e-05	0.000489	CbGpPWpGaD
Dapagliflozin—UGT1A9—Metabolism—CYP27A1—osteoporosis	5.29e-05	0.000489	CbGpPWpGaD
Dapagliflozin—CYP2A6—Metabolism—OXCT1—osteoporosis	5.23e-05	0.000484	CbGpPWpGaD
Dapagliflozin—CYP2A6—Metabolism—CA2—osteoporosis	5.23e-05	0.000484	CbGpPWpGaD
Dapagliflozin—CYP3A4—Phase 1 - Functionalization of compounds—POMC—osteoporosis	5.2e-05	0.00048	CbGpPWpGaD
Dapagliflozin—UGT1A9—Metabolism—ACP5—osteoporosis	5.15e-05	0.000475	CbGpPWpGaD
Dapagliflozin—CYP2A6—Metabolism—MGLL—osteoporosis	5.1e-05	0.000471	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism of lipids and lipoproteins—CYP27A1—osteoporosis	5.09e-05	0.00047	CbGpPWpGaD
Dapagliflozin—UGT1A9—Metabolism of lipids and lipoproteins—GPX1—osteoporosis	5.08e-05	0.000469	CbGpPWpGaD
Dapagliflozin—CYP1A1—Metabolism—GPD2—osteoporosis	5.02e-05	0.000463	CbGpPWpGaD
Dapagliflozin—CYP1A1—Metabolism—PGLS—osteoporosis	5.02e-05	0.000463	CbGpPWpGaD
Dapagliflozin—CYP2A6—NRF2 pathway—TGFB1—osteoporosis	4.95e-05	0.000457	CbGpPWpGaD
Dapagliflozin—ABCB1—Allograft Rejection—TGFB1—osteoporosis	4.81e-05	0.000445	CbGpPWpGaD
Dapagliflozin—UGT1A9—Metabolism—TPI1—osteoporosis	4.78e-05	0.000442	CbGpPWpGaD
Dapagliflozin—CYP3A4—Biological oxidations—CYP19A1—osteoporosis	4.59e-05	0.000424	CbGpPWpGaD
Dapagliflozin—CYP1A1—Metabolism—ATIC—osteoporosis	4.59e-05	0.000424	CbGpPWpGaD
Dapagliflozin—CYP1A1—Metabolism—PNP—osteoporosis	4.59e-05	0.000424	CbGpPWpGaD
Dapagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—ESR1—osteoporosis	4.58e-05	0.000423	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metapathway biotransformation—CYP19A1—osteoporosis	4.53e-05	0.000418	CbGpPWpGaD
Dapagliflozin—UGT2B4—Metabolism—POMC—osteoporosis	4.51e-05	0.000417	CbGpPWpGaD
Dapagliflozin—UGT1A9—Metabolism—P4HB—osteoporosis	4.5e-05	0.000416	CbGpPWpGaD
Dapagliflozin—ABCB1—Allograft Rejection—TNF—osteoporosis	4.5e-05	0.000415	CbGpPWpGaD
Dapagliflozin—UGT1A9—Metabolism—GAPDH—osteoporosis	4.42e-05	0.000408	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism of lipids and lipoproteins—CYP27A1—osteoporosis	4.35e-05	0.000402	CbGpPWpGaD
Dapagliflozin—CYP2A6—Metabolism—IDH2—osteoporosis	4.34e-05	0.000401	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism of lipids and lipoproteins—P4HB—osteoporosis	4.33e-05	0.0004	CbGpPWpGaD
Dapagliflozin—UGT1A9—Metabolism—RAP1A—osteoporosis	4.3e-05	0.000397	CbGpPWpGaD
Dapagliflozin—UGT2B7—Metabolism—ENO1—osteoporosis	4.28e-05	0.000395	CbGpPWpGaD
Dapagliflozin—ABCB1—Metabolism—PKM—osteoporosis	4.23e-05	0.00039	CbGpPWpGaD
Dapagliflozin—ABCB1—Metabolism—FDPS—osteoporosis	4.23e-05	0.00039	CbGpPWpGaD
Dapagliflozin—CYP2D6—Biological oxidations—POMC—osteoporosis	4.22e-05	0.00039	CbGpPWpGaD
Dapagliflozin—UGT2B7—Metabolism—PSMA2—osteoporosis	4.22e-05	0.000389	CbGpPWpGaD
Dapagliflozin—UGT2B7—Metabolism—PSMA5—osteoporosis	4.22e-05	0.000389	CbGpPWpGaD
Dapagliflozin—CYP2C9—Biological oxidations—POMC—osteoporosis	4.19e-05	0.000387	CbGpPWpGaD
Dapagliflozin—CYP2A6—Metabolism—CYP27A1—osteoporosis	4.08e-05	0.000377	CbGpPWpGaD
Dapagliflozin—SLC5A1—Disease—MYC—osteoporosis	4.03e-05	0.000373	CbGpPWpGaD
Dapagliflozin—SLC5A2—Disease—MYC—osteoporosis	4.03e-05	0.000373	CbGpPWpGaD
Dapagliflozin—SLC5A1—Disease—TGFB1—osteoporosis	4.02e-05	0.000372	CbGpPWpGaD
Dapagliflozin—SLC5A2—Disease—TGFB1—osteoporosis	4.02e-05	0.000372	CbGpPWpGaD
Dapagliflozin—ABCB1—Metabolism—GPD2—osteoporosis	4.01e-05	0.00037	CbGpPWpGaD
Dapagliflozin—ABCB1—Metabolism—PGLS—osteoporosis	4.01e-05	0.00037	CbGpPWpGaD
Dapagliflozin—SLC5A4—Disease—IL6—osteoporosis	4e-05	0.00037	CbGpPWpGaD
Dapagliflozin—CYP2D6—Metabolism—PKM—osteoporosis	3.98e-05	0.000368	CbGpPWpGaD
Dapagliflozin—CYP2D6—Metabolism—FDPS—osteoporosis	3.98e-05	0.000368	CbGpPWpGaD
Dapagliflozin—CYP2A6—Metabolism—ACP5—osteoporosis	3.97e-05	0.000366	CbGpPWpGaD
Dapagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—IGF1—osteoporosis	3.96e-05	0.000366	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism—PKM—osteoporosis	3.95e-05	0.000365	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism—FDPS—osteoporosis	3.95e-05	0.000365	CbGpPWpGaD
Dapagliflozin—CYP1A1—Metabolism—OXCT1—osteoporosis	3.9e-05	0.00036	CbGpPWpGaD
Dapagliflozin—CYP1A1—Metabolism—CA2—osteoporosis	3.9e-05	0.00036	CbGpPWpGaD
Dapagliflozin—CYP1A1—Metabolism—MGLL—osteoporosis	3.8e-05	0.000351	CbGpPWpGaD
Dapagliflozin—CYP2D6—Metabolism—PGLS—osteoporosis	3.77e-05	0.000349	CbGpPWpGaD
Dapagliflozin—CYP2D6—Metabolism—GPD2—osteoporosis	3.77e-05	0.000349	CbGpPWpGaD
Dapagliflozin—UGT1A9—Metabolism of lipids and lipoproteins—POMC—osteoporosis	3.75e-05	0.000346	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism—PGLS—osteoporosis	3.74e-05	0.000346	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism—GPD2—osteoporosis	3.74e-05	0.000346	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism of lipids and lipoproteins—P4HB—osteoporosis	3.7e-05	0.000342	CbGpPWpGaD
Dapagliflozin—CYP2A6—Metabolism—TPI1—osteoporosis	3.69e-05	0.000341	CbGpPWpGaD
Dapagliflozin—ABCB1—Metabolism—ATIC—osteoporosis	3.66e-05	0.000338	CbGpPWpGaD
Dapagliflozin—ABCB1—Metabolism—PNP—osteoporosis	3.66e-05	0.000338	CbGpPWpGaD
Dapagliflozin—CYP1A1—Metabolism of lipids and lipoproteins—CYP19A1—osteoporosis	3.58e-05	0.000331	CbGpPWpGaD
Dapagliflozin—CYP1A2—Biological oxidations—POMC—osteoporosis	3.58e-05	0.00033	CbGpPWpGaD
Dapagliflozin—UGT1A9—Metabolism—ENO1—osteoporosis	3.48e-05	0.000321	CbGpPWpGaD
Dapagliflozin—CYP2A6—Metabolism—P4HB—osteoporosis	3.47e-05	0.00032	CbGpPWpGaD
Dapagliflozin—CYP2D6—Metabolism—PNP—osteoporosis	3.45e-05	0.000319	CbGpPWpGaD
Dapagliflozin—CYP2D6—Metabolism—ATIC—osteoporosis	3.45e-05	0.000319	CbGpPWpGaD
Dapagliflozin—UGT1A9—Metabolism—PSMA2—osteoporosis	3.43e-05	0.000316	CbGpPWpGaD
Dapagliflozin—UGT1A9—Metabolism—PSMA5—osteoporosis	3.43e-05	0.000316	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism—ATIC—osteoporosis	3.42e-05	0.000316	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism—PNP—osteoporosis	3.42e-05	0.000316	CbGpPWpGaD
Dapagliflozin—UGT2B7—Metabolism—CYP19A1—osteoporosis	3.42e-05	0.000316	CbGpPWpGaD
Dapagliflozin—CYP2A6—Metabolism—GAPDH—osteoporosis	3.4e-05	0.000314	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism—FDPS—osteoporosis	3.37e-05	0.000312	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism—PKM—osteoporosis	3.37e-05	0.000312	CbGpPWpGaD
Dapagliflozin—CYP2A6—Metabolism—RAP1A—osteoporosis	3.32e-05	0.000306	CbGpPWpGaD
Dapagliflozin—CYP1A1—Metabolism—IDH2—osteoporosis	3.23e-05	0.000299	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism—PGLS—osteoporosis	3.2e-05	0.000295	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism—GPD2—osteoporosis	3.2e-05	0.000295	CbGpPWpGaD
Dapagliflozin—ABCB1—Metabolism—OXCT1—osteoporosis	3.12e-05	0.000288	CbGpPWpGaD
Dapagliflozin—ABCB1—Metabolism—CA2—osteoporosis	3.12e-05	0.000288	CbGpPWpGaD
Dapagliflozin—CYP1A1—Metabolism—CYP27A1—osteoporosis	3.04e-05	0.000281	CbGpPWpGaD
Dapagliflozin—ABCB1—Metabolism—MGLL—osteoporosis	3.04e-05	0.00028	CbGpPWpGaD
Dapagliflozin—SLC5A2—Disease—IL6—osteoporosis	3.03e-05	0.00028	CbGpPWpGaD
Dapagliflozin—SLC5A1—Disease—IL6—osteoporosis	3.03e-05	0.00028	CbGpPWpGaD
Dapagliflozin—CYP1A1—Metabolism—ACP5—osteoporosis	2.96e-05	0.000273	CbGpPWpGaD
Dapagliflozin—CYP2D6—Metabolism—OXCT1—osteoporosis	2.94e-05	0.000271	CbGpPWpGaD
Dapagliflozin—CYP2D6—Metabolism—CA2—osteoporosis	2.94e-05	0.000271	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism—PNP—osteoporosis	2.92e-05	0.00027	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism—ATIC—osteoporosis	2.92e-05	0.00027	CbGpPWpGaD
Dapagliflozin—CYP1A1—Metabolism of lipids and lipoproteins—GPX1—osteoporosis	2.92e-05	0.00027	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism—CA2—osteoporosis	2.91e-05	0.000269	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism—OXCT1—osteoporosis	2.91e-05	0.000269	CbGpPWpGaD
Dapagliflozin—CYP2D6—Metabolism—MGLL—osteoporosis	2.86e-05	0.000264	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism—MGLL—osteoporosis	2.84e-05	0.000262	CbGpPWpGaD
Dapagliflozin—UGT2B7—Metabolism—ADCY5—osteoporosis	2.79e-05	0.000258	CbGpPWpGaD
Dapagliflozin—UGT2B7—Metabolism—GPX1—osteoporosis	2.78e-05	0.000257	CbGpPWpGaD
Dapagliflozin—UGT1A9—Metabolism—CYP19A1—osteoporosis	2.78e-05	0.000257	CbGpPWpGaD
Dapagliflozin—CYP3A4—Biological oxidations—POMC—osteoporosis	2.76e-05	0.000255	CbGpPWpGaD
Dapagliflozin—CYP1A1—Metabolism—TPI1—osteoporosis	2.75e-05	0.000254	CbGpPWpGaD
Dapagliflozin—CYP2A6—Metabolism—ENO1—osteoporosis	2.68e-05	0.000248	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism of lipids and lipoproteins—CYP19A1—osteoporosis	2.67e-05	0.000247	CbGpPWpGaD
Dapagliflozin—CYP2A6—Metabolism—PSMA2—osteoporosis	2.64e-05	0.000244	CbGpPWpGaD
Dapagliflozin—CYP2A6—Metabolism—PSMA5—osteoporosis	2.64e-05	0.000244	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—PKM—osteoporosis	2.6e-05	0.00024	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—FDPS—osteoporosis	2.6e-05	0.00024	CbGpPWpGaD
Dapagliflozin—CYP1A1—Metabolism—P4HB—osteoporosis	2.58e-05	0.000239	CbGpPWpGaD
Dapagliflozin—ABCB1—Metabolism—IDH2—osteoporosis	2.58e-05	0.000238	CbGpPWpGaD
Dapagliflozin—UGT2B7—Metabolism—MTHFR—osteoporosis	2.57e-05	0.000237	CbGpPWpGaD
Dapagliflozin—CYP1A1—Metabolism—GAPDH—osteoporosis	2.54e-05	0.000234	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism—CA2—osteoporosis	2.49e-05	0.00023	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism—OXCT1—osteoporosis	2.49e-05	0.00023	CbGpPWpGaD
Dapagliflozin—CYP1A1—Metabolism—RAP1A—osteoporosis	2.47e-05	0.000228	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—PGLS—osteoporosis	2.47e-05	0.000228	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—GPD2—osteoporosis	2.47e-05	0.000228	CbGpPWpGaD
Dapagliflozin—CYP2D6—Metabolism—IDH2—osteoporosis	2.43e-05	0.000225	CbGpPWpGaD
Dapagliflozin—ABCB1—Metabolism—CYP27A1—osteoporosis	2.43e-05	0.000224	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism—MGLL—osteoporosis	2.42e-05	0.000224	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism—IDH2—osteoporosis	2.41e-05	0.000223	CbGpPWpGaD
Dapagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—MYC—osteoporosis	2.38e-05	0.00022	CbGpPWpGaD
Dapagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—TGFB1—osteoporosis	2.38e-05	0.000219	CbGpPWpGaD
Dapagliflozin—ABCB1—Metabolism—ACP5—osteoporosis	2.36e-05	0.000218	CbGpPWpGaD
Dapagliflozin—CYP2D6—Metabolism—CYP27A1—osteoporosis	2.29e-05	0.000211	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism of lipids and lipoproteins—CYP19A1—osteoporosis	2.29e-05	0.000211	CbGpPWpGaD
Dapagliflozin—UGT1A9—Metabolism—ADCY5—osteoporosis	2.27e-05	0.00021	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism—CYP27A1—osteoporosis	2.27e-05	0.000209	CbGpPWpGaD
Dapagliflozin—UGT1A9—Metabolism—GPX1—osteoporosis	2.26e-05	0.000209	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—ATIC—osteoporosis	2.26e-05	0.000209	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—PNP—osteoporosis	2.26e-05	0.000209	CbGpPWpGaD
Dapagliflozin—CYP2D6—Metabolism—ACP5—osteoporosis	2.22e-05	0.000206	CbGpPWpGaD
Dapagliflozin—ABCB1—Transmembrane transport of small molecules—ADCY5—osteoporosis	2.22e-05	0.000205	CbGpPWpGaD
Dapagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—osteoporosis	2.22e-05	0.000205	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism—ACP5—osteoporosis	2.21e-05	0.000204	CbGpPWpGaD
Dapagliflozin—ABCB1—Metabolism—TPI1—osteoporosis	2.19e-05	0.000203	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism of lipids and lipoproteins—GPX1—osteoporosis	2.18e-05	0.000201	CbGpPWpGaD
Dapagliflozin—CYP1A1—Metabolism of lipids and lipoproteins—POMC—osteoporosis	2.15e-05	0.000199	CbGpPWpGaD
Dapagliflozin—CYP2A6—Metabolism—CYP19A1—osteoporosis	2.14e-05	0.000198	CbGpPWpGaD
Dapagliflozin—UGT1A9—Metabolism—MTHFR—osteoporosis	2.09e-05	0.000193	CbGpPWpGaD
Dapagliflozin—CYP2D6—Metabolism—TPI1—osteoporosis	2.07e-05	0.000191	CbGpPWpGaD
Dapagliflozin—ABCB1—Metabolism—P4HB—osteoporosis	2.06e-05	0.000191	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism—IDH2—osteoporosis	2.06e-05	0.00019	CbGpPWpGaD
Dapagliflozin—UGT2B7—Metabolism—POMC—osteoporosis	2.06e-05	0.00019	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism—TPI1—osteoporosis	2.05e-05	0.000189	CbGpPWpGaD
Dapagliflozin—ABCB1—Metabolism—GAPDH—osteoporosis	2.03e-05	0.000187	CbGpPWpGaD
Dapagliflozin—CYP1A1—Metabolism—ENO1—osteoporosis	2e-05	0.000184	CbGpPWpGaD
Dapagliflozin—ABCB1—Metabolism—RAP1A—osteoporosis	1.97e-05	0.000182	CbGpPWpGaD
Dapagliflozin—CYP1A1—Metabolism—PSMA2—osteoporosis	1.97e-05	0.000182	CbGpPWpGaD
Dapagliflozin—CYP1A1—Metabolism—PSMA5—osteoporosis	1.97e-05	0.000182	CbGpPWpGaD
Dapagliflozin—CYP2D6—Metabolism—P4HB—osteoporosis	1.94e-05	0.00018	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism—CYP27A1—osteoporosis	1.94e-05	0.000179	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism—P4HB—osteoporosis	1.93e-05	0.000178	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—CA2—osteoporosis	1.92e-05	0.000177	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—OXCT1—osteoporosis	1.92e-05	0.000177	CbGpPWpGaD
Dapagliflozin—CYP2D6—Metabolism—GAPDH—osteoporosis	1.91e-05	0.000176	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism—GAPDH—osteoporosis	1.89e-05	0.000175	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism—ACP5—osteoporosis	1.88e-05	0.000174	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—MGLL—osteoporosis	1.87e-05	0.000173	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism of lipids and lipoproteins—GPX1—osteoporosis	1.86e-05	0.000172	CbGpPWpGaD
Dapagliflozin—CYP2D6—Metabolism—RAP1A—osteoporosis	1.86e-05	0.000172	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism—RAP1A—osteoporosis	1.84e-05	0.00017	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism—TPI1—osteoporosis	1.75e-05	0.000162	CbGpPWpGaD
Dapagliflozin—CYP2A6—Metabolism—ADCY5—osteoporosis	1.75e-05	0.000162	CbGpPWpGaD
Dapagliflozin—CYP2A6—Metabolism—GPX1—osteoporosis	1.74e-05	0.000161	CbGpPWpGaD
Dapagliflozin—UGT1A9—Metabolism—POMC—osteoporosis	1.67e-05	0.000154	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism—P4HB—osteoporosis	1.65e-05	0.000152	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism—GAPDH—osteoporosis	1.62e-05	0.000149	CbGpPWpGaD
Dapagliflozin—CYP2A6—Metabolism—MTHFR—osteoporosis	1.61e-05	0.000149	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism of lipids and lipoproteins—POMC—osteoporosis	1.61e-05	0.000148	CbGpPWpGaD
Dapagliflozin—CYP1A1—Metabolism—CYP19A1—osteoporosis	1.6e-05	0.000147	CbGpPWpGaD
Dapagliflozin—ABCB1—Metabolism—ENO1—osteoporosis	1.59e-05	0.000147	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—IDH2—osteoporosis	1.59e-05	0.000147	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism—RAP1A—osteoporosis	1.57e-05	0.000145	CbGpPWpGaD
Dapagliflozin—ABCB1—Metabolism—PSMA2—osteoporosis	1.57e-05	0.000145	CbGpPWpGaD
Dapagliflozin—ABCB1—Metabolism—PSMA5—osteoporosis	1.57e-05	0.000145	CbGpPWpGaD
Dapagliflozin—CYP2D6—Metabolism—ENO1—osteoporosis	1.5e-05	0.000139	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—CYP27A1—osteoporosis	1.5e-05	0.000138	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism—ENO1—osteoporosis	1.49e-05	0.000138	CbGpPWpGaD
Dapagliflozin—CYP2D6—Metabolism—PSMA2—osteoporosis	1.48e-05	0.000137	CbGpPWpGaD
Dapagliflozin—CYP2D6—Metabolism—PSMA5—osteoporosis	1.48e-05	0.000137	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism—PSMA2—osteoporosis	1.47e-05	0.000136	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism—PSMA5—osteoporosis	1.47e-05	0.000136	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—ACP5—osteoporosis	1.45e-05	0.000134	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism of lipids and lipoproteins—POMC—osteoporosis	1.37e-05	0.000127	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—TPI1—osteoporosis	1.35e-05	0.000125	CbGpPWpGaD
Dapagliflozin—CYP1A1—Metabolism—ADCY5—osteoporosis	1.3e-05	0.00012	CbGpPWpGaD
Dapagliflozin—CYP1A1—Metabolism—GPX1—osteoporosis	1.3e-05	0.00012	CbGpPWpGaD
Dapagliflozin—CYP2A6—Metabolism—POMC—osteoporosis	1.29e-05	0.000119	CbGpPWpGaD
Dapagliflozin—ABCB1—Metabolism—CYP19A1—osteoporosis	1.27e-05	0.000118	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism—ENO1—osteoporosis	1.27e-05	0.000118	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—P4HB—osteoporosis	1.27e-05	0.000117	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism—PSMA2—osteoporosis	1.25e-05	0.000116	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism—PSMA5—osteoporosis	1.25e-05	0.000116	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—GAPDH—osteoporosis	1.25e-05	0.000115	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—RAP1A—osteoporosis	1.22e-05	0.000112	CbGpPWpGaD
Dapagliflozin—CYP2D6—Metabolism—CYP19A1—osteoporosis	1.2e-05	0.000111	CbGpPWpGaD
Dapagliflozin—CYP1A1—Metabolism—MTHFR—osteoporosis	1.2e-05	0.000111	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism—CYP19A1—osteoporosis	1.19e-05	0.00011	CbGpPWpGaD
Dapagliflozin—ABCB1—Metabolism—ADCY5—osteoporosis	1.04e-05	9.62e-05	CbGpPWpGaD
Dapagliflozin—ABCB1—Metabolism—GPX1—osteoporosis	1.04e-05	9.59e-05	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism—CYP19A1—osteoporosis	1.02e-05	9.4e-05	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—ENO1—osteoporosis	9.83e-06	9.08e-05	CbGpPWpGaD
Dapagliflozin—CYP2D6—Metabolism—ADCY5—osteoporosis	9.82e-06	9.07e-05	CbGpPWpGaD
Dapagliflozin—CYP2D6—Metabolism—GPX1—osteoporosis	9.78e-06	9.04e-05	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism—ADCY5—osteoporosis	9.73e-06	8.99e-05	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism—GPX1—osteoporosis	9.7e-06	8.96e-05	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—PSMA2—osteoporosis	9.68e-06	8.94e-05	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—PSMA5—osteoporosis	9.68e-06	8.94e-05	CbGpPWpGaD
Dapagliflozin—CYP1A1—Metabolism—POMC—osteoporosis	9.59e-06	8.86e-05	CbGpPWpGaD
Dapagliflozin—ABCB1—Metabolism—MTHFR—osteoporosis	9.58e-06	8.85e-05	CbGpPWpGaD
Dapagliflozin—CYP2D6—Metabolism—MTHFR—osteoporosis	9.03e-06	8.34e-05	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism—MTHFR—osteoporosis	8.95e-06	8.27e-05	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism—ADCY5—osteoporosis	8.32e-06	7.68e-05	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism—GPX1—osteoporosis	8.29e-06	7.66e-05	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—CYP19A1—osteoporosis	7.85e-06	7.26e-05	CbGpPWpGaD
Dapagliflozin—ABCB1—Metabolism—POMC—osteoporosis	7.66e-06	7.08e-05	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism—MTHFR—osteoporosis	7.65e-06	7.06e-05	CbGpPWpGaD
Dapagliflozin—CYP2D6—Metabolism—POMC—osteoporosis	7.22e-06	6.67e-05	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism—POMC—osteoporosis	7.16e-06	6.61e-05	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—ADCY5—osteoporosis	6.42e-06	5.93e-05	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—GPX1—osteoporosis	6.4e-06	5.91e-05	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism—POMC—osteoporosis	6.12e-06	5.65e-05	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—MTHFR—osteoporosis	5.9e-06	5.45e-05	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—POMC—osteoporosis	4.72e-06	4.36e-05	CbGpPWpGaD
